Loyola University Medical Center, Maywood, Illinois.
Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Spine (Phila Pa 1976). 2019 Jul 15;44(14):E815-E822. doi: 10.1097/BRS.0000000000002987.
Rat posterolateral arthrodesis model.
Quantify the impact of administration of a proton pump inhibitor on spine fusion.
Proton pump inhibitors (PPIs) are widely used for gastrointestinal disorders and for ulcer prophylaxis in patients taking non-steroidal anti-inflammatory drugs. PPIs cause chronic acid suppression which has been found to result in decreased bone mineral density, increased fracture risk, and impaired fracture healing. Despite advances in surgical techniques, pseudarthrosis still occurs in up to 24% of patients requiring revision surgery following spinal fusion procedures. Thus, there are likely many unidentified risk factors. While PPIs have been hypothesized to impact fracture healing, no study has evaluated their effect on spine arthrodesis rates.
Thirty-eight female rats underwent posterolateral lumbar spinal fusion. Rats were divided into two groups: normal saline control and pantroprazole, which was administered by daily intraperitoneal injections. At 8 weeks postoperative spines were evaluated with manual palpation, microCT, histologic analysis, and biomechanical testing.
Fusion rates of the control group and PPI group were not significantly different (100% vs. 94%). Average fusion scores were significantly lower in the pantoprazole group. New bone formation identified on microCT imaging of bilaterally fused specimens demonstrated a lower average volume of newly generated bone in the PPI group, but this difference was not significant. Biomechanical testing demonstrated no significant difference in strength or stiffness of the fusion mass between the groups.
This study demonstrates that administration of PPIs does not inhibit fusion rates, bone formation, or affect biomechanical integrity of fusion. However, lower fusion scores in the PPI group suggest that a negative impact may still exist. Future studies will explore growth factor and protein expression in the fusion masses as well as utilize higher doses of PPI to fully discern their effect on spine fusion.
N/A.
大鼠后路关节融合模型。
定量评估质子泵抑制剂(PPI)给药对脊柱融合的影响。
质子泵抑制剂(PPIs)广泛用于胃肠道疾病和预防非甾体抗炎药相关溃疡。PPIs 可导致慢性酸抑制,从而导致骨密度降低、骨折风险增加和骨折愈合受损。尽管手术技术不断进步,但在接受脊柱融合手术后需要翻修手术的患者中,假关节仍然高达 24%。因此,可能存在许多未被识别的风险因素。虽然有假说认为 PPI 会影响骨折愈合,但尚无研究评估其对脊柱关节融合率的影响。
38 只雌性大鼠接受后路腰椎脊柱融合术。大鼠分为两组:生理盐水对照组和泮托拉唑组,通过每日腹腔内注射给药。术后 8 周,通过手动触诊、微 CT、组织学分析和生物力学测试评估脊柱。
对照组和 PPI 组的融合率无显著差异(100%比 94%)。泮托拉唑组的平均融合评分明显较低。双侧融合标本的微 CT 成像显示新骨形成,PPI 组新生骨的平均体积较低,但差异无统计学意义。生物力学测试表明两组融合块的强度或刚度无显著差异。
本研究表明,PPI 的给药不会抑制融合率、骨形成或影响融合的生物力学完整性。然而,PPI 组的融合评分较低表明仍可能存在负面影响。未来的研究将探索融合块中的生长因子和蛋白表达,并使用更高剂量的 PPI 来全面了解其对脊柱融合的影响。
无。